A nose spray vaccine slowed brain tumors in mice
Original title: Nanohydrogel Composite Vaccine Capable of Bypassing the Blood-Brain Barrier and Targeting Tumors for Glioblastoma Immunotherapy via Intranasal Immunization.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in lab cells and in mice.
The short version
A vaccine given through the nose helped mice with brain tumors live longer.
What was studied. Scientists built a gel based vaccine for glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary, a brain cancer. They sprayed it into the nose of mice that had brain tumors, with 8 mice in each group. They also tested it on cells in the lab.
What they found. Mice that did not get the vaccine lived 21 days. Mice that got it lived more than 60 days, which is 2.8 times longer. At day 21, tumor tissue was 82.5% smaller in the treated mice. Immune cells that attack tumors went up 9.5 times inside the tumor.
What this means, and what it doesn't
What it could mean: The nose may be a way to get medicine past the brain's natural shield. That idea is worth testing further. It is not something a doctor can give a patient now.
What it doesn't mean: This is not a cure and not a treatment yet. The work was done in lab cells and in mice, not in people. Mouse tumors do not always act like human ones. Tests in people would need to check safety first, and that takes years.
Source: PubMed, September 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.